

# Chapter 124

## Cutaneous Melanoma

Evans C. Bailey, Arthur J. Sober,  
Hensin Tsao, Martin C. Mihm Jr,  
& Timothy M. Johnson

### REFERENCES

1. Horner MJRL, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK, eds.: *SEER Cancer Statistics Review*, [http://seer.cancer.gov/csr/1975\\_2006/](http://seer.cancer.gov/csr/1975_2006/), 2010.
2. Jemal A et al: Cancer statistics, 2009. *CA Cancer J Clin* **59**(4):225-249, 2009
3. Geller AC et al: Melanoma incidence and mortality among US whites, 1969-1999. *JAMA* **288**(14):1719-1720, 2002
4. Purdue MP et al: Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. *J Invest Dermatol* **128**(12):2905-2908, 2008
5. Elwood JM, Jopson J: Melanoma and sun exposure: An overview of published studies. *Int J Cancer* **73**(2):198-203, 1997
6. Oliveria SA, Saraiya M et al: Sun exposure and risk of melanoma. *Arch Dis Child* **91**(2):131-138, 2006
7. Saraiya M, Hall HI, Uhler RJ: Sunburn prevalence among adults in the United States, 1999. *Am J Prev Med* **23**(2):91-97, 2002
8. Langley RG, Sober AJ: A clinical review of the evidence for the role of ultraviolet radiation in the etiology of cutaneous melanoma. *Cancer Invest* **15**(6):561-567, 1997
9. Berwick M, Wiggins C: The current epidemiology of cutaneous malignant melanoma. *Front Biosci* **11**:1244-1254, 2006
10. Eide MJ, Weinstock MA: Association of UV index, latitude, and melanoma incidence in nonwhite populations—US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. *Arch Dermatol* **141**(4):477-481, 2005
11. Gillgren P et al: A new computerized methodology to analyse tumour site in relation to phenotypic traits and epidemiological characteristics of cutaneous malignant melanoma. *Br J Dermatol* **146**(6):1023-1030, 2002
12. Elwood JM, Gallagher RP: Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. *Int J Cancer* **78**(3):276-280, 1998
13. Stern RS: The risk of melanoma in association with long-term exposure to PUVA. *J Am Acad Dermatol* **44**(5):755-761, 2001
14. Stern RS, Nichols KT, Vakeva LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* **336**(15):1041-1045, 1997
15. Whitmore SE, Morison WL: Melanoma after PUVA therapy for psoriasis. *N Engl J Med* **337**(7):502-503, 1997
16. Gallagher RP, Spinelli JJ, Lee TK: Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. *Cancer Epidemiol Biomarkers Prev* **14**(3):562-566, 2005
17. The International Agency for research on cancer Working Group on artificial ultraviolet (UV) light and skin cancer: The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. *Int J Cancer* **120**(5):1116-1122, 2007
18. Holly EA et al: Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. *Am J Epidemiol* **141**(10):934-942, 1995
19. Holly EA et al: Cutaneous melanoma in women. I. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. *Am J Epidemiol* **141**(10):923-933, 1995
20. Naldi L et al: Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: A case-control study from Italy. *Ann Epidemiol* **15**(7):545-550, 2005
21. Titus-Ernstoff L et al: Pigmentary characteristics and moles in relation to melanoma risk. *Int J Cancer* **116**(1):144-149, 2005
22. Veierod MB et al: A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. *J Natl Cancer Inst* **95**(20):1530-1538, 2003
23. Garbe C et al: Associated factors in the prevalence of more than 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentiginos: Multicenter case-control study of the

- Central Malignant Melanoma Registry of the German Dermatological Society. *J Invest Dermatol* **102**(5):700-705, 1994
24. Garbe C et al: Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: Multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. *J Invest Dermatol* **102**(5):695-699, 1994
  25. Goldstein AM et al: The inheritance pattern of dysplastic naevi in families of dysplastic naevus patients. *Melanoma Res* **3**(1):15-22, 1993
  26. Tucker MA et al: Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. *JAMA* **277**(18):1439-1444, 1997
  27. Bevona C et al: Cutaneous melanomas associated with nevi. *Arch Dermatol* **139**(12):1620-1624; discussion 1624, 2003
  28. Tromberg J et al: Congenital melanocytic nevi needing treatment. *Dermatol Ther* **18**(2):136-150, 2005
  29. Niendorf KB, Tsao H. Cutaneous melanoma: Family screening and genetic testing. *Dermatol Ther* **19**(1):1-8, 2006
  30. Ferrone CR et al: Clinicopathological features of and risk factors for multiple primary melanomas. *JAMA* **294**(13):1647-1654, 2005
  31. Johnson TM, Hamilton T, Lowe L: Multiple primary melanomas. *J Am Acad Dermatol* **39**(3):422-427, 1998
  32. Lanoy E, Costagliola D, Engels EA: Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. *Int J Cancer* **126**(7):1724-1731, 2010
  33. Lanoy E et al: Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. *AIDS* **23**(3):385-393, 2009
  34. Hu S et al: Skin cancer and non-Hodgkin's lymphoma: Examining the link. *Dermatol Surg* **31**(1):76-82, 2005
  35. McIntosh BC et al: Metachronous primary melanoma and lymphoma. *Ann Plast Surg* **64**(2):229-232
  36. Tsao H, Kwitkiwski K, Sober AJ: A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. *J Am Acad Dermatol* **46**(1):55-61, 2002
  37. Bishop DT et al: Geographical variation in the penetrance of CDKN2A mutations for melanoma. *J Natl Cancer Inst* **94**(12):894-903, 2002
  38. Hansen CB et al: Clinical germline genetic testing for melanoma. *Lancet Oncol* **5**(5):314-319, 2004
  39. Sharpless E, Chin L: The INK4a/ARF locus and melanoma. *Oncogene* **22**(20):3092-3098, 2003
  40. Davies H et al: Mutations of the BRAF gene in human cancer. *Nature* **417**(6892):949-954, 2002
  41. Wan PT et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* **116**(6):855-867, 2004
  42. Curtin JA et al: Distinct sets of genetic alterations in melanoma. *N Engl J Med* **353**(20):2135-2147, 2005
  43. Tsao H et al: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. *J Invest Dermatol* **122**(2):337-341, 2004
  44. Dankort D et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* **41**(5):544-552, 2009
  45. Garraway LA et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* **436**(7047):117-122, 2005
  46. Curtin JA et al: Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* **24**(26):4340-4346, 2006
  47. Beadling C et al: KIT gene mutations and copy number in melanoma subtypes. *Clin Cancer Res* **14**(21):6821-6828, 2008
  48. Hodi FS et al: Major response to imatinib mesylate in KIT-mutated melanoma. *J Clin Oncol* **26**(12):2046-2051, 2008
  49. Valverde P et al: Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. *Nat Genet* **11**(3):328-330, 1995
  50. Sturm RA: Skin colour and skin cancer—MC1R, the genetic link. *Melanoma Res* **12**(5):405-416, 2002
  51. Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium. *J Natl Cancer Inst* **91**(15):1310-1316, 1999
  52. Udayakumar D, Tsao H: Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: Lessons from genome-wide association studies. *Genome Med* **1**(10):95, 2009
  53. Brown KM et al: Common sequence variants on 20q11.22 confer melanoma susceptibility. *Nat Genet* **40**(7):838-840, 2008
  54. Bishop DT et al: Genome-wide association study identifies three loci associated with melanoma risk. *Nat Genet* **41**(8):920-925, 2009

55. Miller AJ, Mihm MC Jr: Melanoma. *N Engl J Med* **355**(1):51-65, 2006
56. Demierre MF et al: Early detection of thick melanomas in the United States: Beware of the nodular subtype. *Arch Dermatol* **141**(6):745-750, 2005
57. Weinstock MA, Sober AJ: The risk of progression of lentigo maligna to lentigo maligna melanoma. *Br J Dermatol* **116**(3):303-310, 1987
58. Fortin PT et al: Malignant melanoma of the foot and ankle. *J Bone Joint Surg Am* **77**(9):1396-1403, 1995
59. Hawkins WG et al: Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma. *Ann Surg Oncol* **12**(3):207-213, 2005
60. Busam KJ et al: Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. *J Invest Dermatol* **124**(2):412-418, 2005
61. Wechter ME et al: Vulvar melanoma: A report of 20 cases and review of the literature. *J Am Acad Dermatol* **50**(4):554-562, 2004
62. Farber M, Schutzer P, Mihm MC Jr: Pigmented lesions of the conjunctiva. *J Am Acad Dermatol* **38**(6 Pt 1):971-978, 1998
63. Rodriguez-Sains RS: Pigmented conjunctival neoplasms. *Orbit* **21**(3):231-238, 2002
64. Magro CM, Crowson AN, Mihm MC: Unusual variants of malignant melanoma. *Mod Pathol* **19**(Suppl 2):S41-70, 2006
65. Ludgate MW et al: The atypical Spitz tumor of uncertain biologic potential: A series of 67 patients from a single institution. *Cancer* **115**(3):631-641, 2009
66. Ludgate MW et al: Animal-type melanoma: A clinical and histopathological study of 22 cases from a single institution. *Br J Dermatol* **162**(1):129-136, 2010
67. Schwartz JL, Mozurkewich EL, Johnson TM: Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. *Cancer* **97**(9):2130-2133, 2003
68. Karagas MR et al: Pregnancy history and incidence of melanoma in women: A pooled analysis. *Cancer Causes Control* **17**(1):11-19, 2006
69. Wiggins CL, Berwick M, Bishop JA: Malignant melanoma in pregnancy. *Obstet Gynecol Clin North Am* **32**(4):559-568, 2005
70. Lens M, Rosdahl I, Newton-Bishop J: Cutaneous melanoma during pregnancy: Is the controversy over? *J Clin Oncol* **27**(19):e11-12; author reply e13-14, 2009
71. Lens MB et al: Effect of pregnancy on survival in women with cutaneous malignant melanoma. *J Clin Oncol* **22**(21):4369-4375, 2004
72. O'Meara AT et al: Malignant melanoma in pregnancy. A population-based evaluation. *Cancer* **103**(6):1217-1226, 2005
73. Ceballos PI, Ruiz-Maldonado R, Mihm MC Jr: Melanoma in children. *N Engl J Med* **332**(10):656-662, 1995
74. Sharfman W, Lange J, Balch CM: Pediatric melanoma. *Pediatr Blood Cancer* **44**(5):431-432, 2005
75. Strouse JJ et al: Pediatric melanoma: Risk factor and survival analysis of the surveillance, epidemiology and end results database. *J Clin Oncol* **23**(21):4735-4741, 2005
76. Friedman RJ, Rigel DS, Kopf AW: Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. *CA Cancer J Clin* **35**(3):130-151, 1985
77. Whited JD, Grichnik JM: The rational clinical examination. Does this patient have a mole or a melanoma? *JAMA* **279**(9):696-701, 1998
78. Gachon J et al: First prospective study of the recognition process of melanoma in dermatological practice. *Arch Dermatol* **141**(4):434-438, 2005
79. Abbasi NR et al: Early diagnosis of cutaneous melanoma: Revisiting the ABCD criteria. *JAMA* **292**(22):2771-2776, 2004
80. Liu W et al: What features do patients notice that help to distinguish between benign pigmented lesions and melanomas?: The ABCD(E) rule versus the seven-point checklist. *Melanoma Res* **15**(6):549-554, 2005
81. Schwartz JL et al: Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. *Cancer* **95**(7):1562-1568, 2002
82. Nagore E et al: Primary cutaneous melanoma in hidden sites is associated with thicker tumours—A study of 829 patients. *Eur J Cancer* **37**(1):79-82, 2001
83. Menzies SW: Cutaneous melanoma: Making a clinical diagnosis, present and future. *Dermatol Ther* **19**(1):32-39, 2006
84. Weinstock MA: Cutaneous melanoma: Public health approach to early detection. *Dermatol Ther* **19**(1):26-31, 2006

85. Noor O 2nd, Nanda A, Rao BK: A dermoscopy survey to assess who is using it and why it is or is not being used. *Int J Dermatol* **48**(9):951-952, 2009
86. Argenziano G et al: Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermoscopy and a new 7-point checklist based on pattern analysis. *Arch Dermatol* **134**(12):1563-1570, 1998
87. Blum A, Rassner G, Garbe C: Modified ABC-point list of dermoscopy: A simplified and highly accurate dermoscopic algorithm for the diagnosis of cutaneous melanocytic lesions. *J Am Acad Dermatol* **48**(5):672-678, 2003
88. Henning JS et al: The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. *J Am Acad Dermatol* **56**(1):45-52, 2007
89. Menzies SW et al: Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. *Arch Dermatol* **132**(10):1178-1182, 1996
90. Nachbar F et al: The ABCD rule of dermoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. *J Am Acad Dermatol* **30**(4):551-559, 1994
91. Pehamberger H, Steiner A, Wolff K: In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. *J Am Acad Dermatol* **17**(4):571-583, 1987
92. Annessi G et al: Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: The importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. *J Am Acad Dermatol* **56**(5):759-767, 2007
93. Carli P et al: Pattern analysis, not simplified algorithms, is the most reliable method for teaching dermoscopy for melanoma diagnosis to residents in dermatology. *Br J Dermatol* **148**(5):981-984, 2003
94. Dolianitis C et al: Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. *Arch Dermatol* **141**(8):1008-1014, 2005
95. Goodson AG, Grossman D: Strategies for early melanoma detection: Approaches to the patient with nevi. *J Am Acad Dermatol* **60**(5):719-735; quiz 736-718, 2009
96. Lien MH, Sondak VK: Diagnostic techniques for primary cutaneous melanoma. *G Ital Dermatol Venereol* **144**(2):187-194, 2009
97. Corona R et al: Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. *J Clin Oncol* **14**(4):1218-1223, 1996
98. Farmer ER, Gonin R, Hanna MP: Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. *Hum Pathol* **27**(6):528-531, 1996
99. McGinnis KS et al: Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. *Arch Dermatol* **138**(5):617-621, 2002
100. Sober AJ et al: Guidelines of care for primary cutaneous melanoma. *J Am Acad Dermatol* **45**(4):579-586, 2001
101. Davis IJ et al: Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MIT family of human cancers. *Cancer Cell* **9**(6):473-484, 2006
102. Balch CM et al: Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* **27**(36):6199-6206, 2009
103. Edge SB et al: *AJCC Cancer Staging Manual*, 7th edition. Netherlands, Springer Science+Business Media, 2010.
104. Balch CM et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol* **19**(16):3635-3648, 2001
105. Balch CM et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* **19**(16):3622-3634, 2001
106. Azzola MF et al: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3661 patients from a single center. *Cancer* **97**(6):1488-1498, 2003
107. Busam KJ: The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. *Ann Surg Oncol* **11**(4):360-361, 2004
108. Francken AB et al: The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. *Ann Surg Oncol* **11**(4):426-433, 2004
109. Gimotty PA et al: Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. *J Clin Oncol* **25**(9):1129-1134, 2007
110. Kesmodel SB et al: Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. *Ann Surg Oncol* **12**(6):449-458, 2005

111. Paek SC et al: The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. *Cancer* **109**(1):100-108, 2007
112. Thompson JF, et al: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. *J Clin Oncol* **29**(16):2199-205, 2011
113. Homsy J et al: Cutaneous melanoma: Prognostic factors. *Cancer Control* **12**(4):223-229, 2005
114. Leong SP et al: Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. *World J Surg* **29**(6):683-691, 2005
115. Garbe C et al: Primary cutaneous melanoma. Prognostic classification of anatomic location. *Cancer* **75**(10):2492-2498, 1995
116. Gershenwald JE et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. *J Clin Oncol* **17**(3):976-983, 1999
117. Morton DL et al: Sentinel-node biopsy or nodal observation in melanoma. *N Engl J Med* **355**(13):1307-1317, 2006
118. Coit DG et al: Melanoma. *J Natl Compr Canc Netw* **7**(3):250-275, 2009
119. Sabel MS, Wong SL: Review of evidence-based support for pretreatment imaging in melanoma. *J Natl Compr Canc Netw* **7**(3):281-289, 2009
120. Tsao H et al: Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. *Arch Dermatol* **140**(1):67-70, 2004
121. Crowley NJ, Seigler HF: Late recurrence of malignant melanoma. Analysis of 168 patients. *Ann Surg* **212**(2):173-177, 1990
122. Tsao H, Cosimi AB, Sober AJ: Ultra-late recurrence (15 years or longer) of cutaneous melanoma. *Cancer* **79**(12):2361-2370, 1997
123. Cormier JN et al: Metastatic melanoma to lymph nodes in patients with unknown primary sites. *Cancer* **106**(9):2012-2020, 2006
124. Chang P, Knapper WH: Metastatic melanoma of unknown primary. *Cancer* **49**(6):1106-1111, 1982
125. Schlagenhauff B et al: Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: Recommendations for initial staging examinations. *Cancer* **80**(1):60-65, 1997
126. Bowen GM et al: Solitary melanoma confined to the dermal and/or subcutaneous tissue: Evidence for revisiting the staging classification. *Arch Dermatol* **136**(11):1397-1399, 2000
127. Swetter SM et al: Primary dermal melanoma: A distinct subtype of melanoma. *Arch Dermatol* **140**(1):99-103, 2004
128. Karimipour DJ et al: Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. *J Am Acad Dermatol* **52**(5):798-802, 2005
129. McMasters KM et al: Interval sentinel lymph nodes in melanoma. *Arch Surg* **137**(5):543-547; discussion 547-549, 2002
130. Uren RF, Howman-Giles R, Thompson JF: Patterns of lymphatic drainage from the skin in patients with melanoma. *J Nucl Med* **44**(4):570-582, 2003
131. Basler GC et al: The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. *J Am Acad Dermatol* **36**(3 Pt 1):403-408, 1997
132. Clark PB et al: Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. *Arch Surg* **141**(3):284-288, 2006
133. Hafner J et al: Baseline staging in cutaneous malignant melanoma. *Br J Dermatol* **150**(4):677-686, 2004
134. Wagner JD et al: Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. *Cancer* **104**(3):570-579, 2005
135. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. *N Engl J Med* **351**(10):998-1012, 2004
136. Miranda EP et al: Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Arch Surg* **139**(8):831-836; discussion 836-837, 2004
137. Morton DL et al: Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. *J Clin Oncol* **11**(9):1751-1756, 1993
138. Morton DL et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg* **127**(4):392-399, 1992
139. Thompson JF et al: The history and future of melanoma staging. *J Surg Oncol* **86**(4):224-235, 2004

140. Morton DL, Cochran AJ: The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. *Br J Dermatol* **151**(2):308-319, 2004
141. Mraz-Gernhard S et al: Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. *Arch Dermatol* **134**(8):983-987, 1998
142. Sondak VK et al: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. *Ann Surg Oncol* **11**(3):247-258, 2004
143. Staius Muller MG et al: The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. *Cancer* **91**(12):2401-2408, 2001
144. Johnson TM et al: Staging workup, sentinel node biopsy, and follow-up tests for melanoma: Update of current concepts. *Arch Dermatol* **140**(1):107-113, 2004
145. Wang TS et al: Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. *J Am Acad Dermatol* **51**(3):399-405, 2004
146. Balch CM et al: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. *Ann Surg Oncol* **8**(2):101-108, 2001
147. Cohn-Cedermark G et al: Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. *Cancer* **89**(7):1495-1501, 2000
148. Johnson TM, Sondak VK: Melanoma margins: The importance and need for more evidence-based trials. *Arch Dermatol* **140**(9):1148-1150, 2004
149. Khayat D et al: Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer* **97**(8):1941-1946, 2003
150. Krown SE, Chapman PB: Defining adequate surgery for primary melanoma. *N Engl J Med* **350**(8):823-825, 2004
151. Thomas JM et al: Excision margins in high-risk malignant melanoma. *N Engl J Med* **350**(8):757-766, 2004
152. Veronesi U, Cascinelli N: Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg* **126**(4):438-441, 1991
153. Zalla MJ et al: Mohs micrographic excision of melanoma using immunostains. *Dermatol Surg* **26**(8):771-784, 2000
154. Zitelli JA, Brown CD, Hanusa BH: Surgical margins for excision of primary cutaneous melanoma. *J Am Acad Dermatol* **37**(3 Pt 1):422-429, 1997
155. Demirci H et al: Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. *Ophthalmology* **115**(12):2295-2300, e2293, 2008
156. Bub JL et al: Management of lentigo maligna and lentigo maligna melanoma with staged excision: A 5-year follow-up. *Arch Dermatol* **140**(5):552-558, 2004
157. Anderson KW et al: Treatment of head and neck melanoma, lentigo maligna subtype: A practical surgical technique. *Arch Facial Plast Surg* **3**(3):202-206, 2001
158. Prieto VG et al: Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? *Am J Clin Pathol* **120**(2):203-208, 2003
159. Florell SR et al: Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: An interobserver comparison study. *Arch Dermatol* **139**(5):595-604, 2003
160. Young SE et al: Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? *Cancer J* **12**(3):207-211, 2006
161. Balch CM et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. *Ann Surg* **224**(3):255-263; discussion 263-256, 1996
162. Cascinelli N et al: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. *Lancet* **351**(9105):793-796, 1998
163. Cascinelli N et al: World Health Organization experience in the treatment of melanoma. *Surg Clin North Am* **83**(2):405-416, 2003
164. Morton DL et al: Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg* **242**(3):302-311; discussion 311-303, 2005
165. Sabel MS et al: Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. *J Am Coll Surg* **201**(1):37-47, 2005
166. Ghaferi AA et al: Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. *Ann Surg Oncol* **16**(11):2978-2984, 2009
167. Sabel MS et al: Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. *Surgery* **141**(6):728-735, 2007

168. Kirkwood JM et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. *J Clin Oncol* **18**(12):2444-2458, 2000
169. Kirkwood JM et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* **14**(1):7-17, 1996
170. Verma S et al: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. *Cancer* **106**(7):1431-1442, 2006
171. Anaya DA et al: Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. *Cancer* **112**(9):2030-2037, 2008
172. Gogas H et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. *N Engl J Med* **354**(7):709-718, 2006
173. Cole BF et al: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. *J Clin Oncol* **14**(10):2666-2673, 1996
174. Kilbridge KL et al: Patient preferences for adjuvant interferon alfa-2b treatment. *J Clin Oncol* **19**(3):812-823, 2001
175. Jandus C, Speiser D, Romero P: Recent advances and hurdles in melanoma immunotherapy. *Pigment Cell Melanoma Res* **22**(6):711-723, 2009
176. Grunhagen DJ et al: Isolated limb perfusion for melanoma patients—A review of its indications and the role of tumour necrosis factor-alpha. *Eur J Surg Oncol* **32**(4):371-380, 2006
177. Thompson JF, Kam PC: Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. *J Surg Oncol* **88**(1):1-3, 2004
178. Tagawa ST et al: Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. *Cancer* **106**(6):1353-1357, 2006
179. Tarhini AA, Agarwala SS: Cutaneous melanoma: Available therapy for metastatic disease. *Dermatol Ther* **19**(1):19-25, 2006
180. Middleton MR et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* **18**(1):158-166, 2000
181. Atkins MB et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* **17**(7):2105-2116, 1999
182. Eton O et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. *J Clin Oncol* **20**(8):2045-2052, 2002
183. Hauschild A et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *J Clin Oncol* **27**(17):2823-2830, 2009
184. Flaherty KT et al: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. *J Clin Oncol* **24**, 2009.
185. Garber K: Cancer research. Melanoma drug vindicates targeted approach. *Science* **326**(5960):1619, 2009
186. Sondak VK, Smalley K: Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. *Pigment Cell Melanoma Res* **22**(4):386-387, 2009
187. Chapman PB, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* **364**(26):2507-2516, 2011
188. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. *Pigment Cell Melanoma Res* **21**(4):492-493, 2008

